Provider Briefing: The Difluprednate Shortage in 2026

The Difluprednate ophthalmic emulsion shortage has now persisted for nearly two years, creating ongoing challenges for ophthalmologists, optometrists, and the surgical teams that depend on this potent topical corticosteroid. This briefing provides a concise, evidence-based overview of the current situation and actionable steps for managing your prescribing workflow.

If you're seeing increased patient calls about unfilled Difluprednate prescriptions, you're not alone. Understanding the scope of this shortage — and having a clear backup plan — will help you maintain continuity of care.

Shortage Timeline

• April 2024: ASHP first reports the Difluprednate shortage after generic manufacturer Exelan places its 0.05% ophthalmic emulsion (5 mL) on back order
• Mid-2024: Supply constraints worsen as other generic sources fail to scale production to meet demand
• August 2025: ASHP updates the shortage listing — Exelan remains on long-term back order with no estimated release date
• Early 2026: Shortage continues. Brand-name Durezol (Novartis/Alcon) remains available but at significantly higher cost. Dr. Reddy's generic is available in limited quantities.

The core issue is manufacturing capacity. Difluprednate's castor oil-based emulsion formulation is technically challenging to produce, creating high barriers to entry for additional generic manufacturers.

Prescribing Implications

Impact on Post-Surgical Protocols

Many ophthalmology practices have standardized on Difluprednate as the first-line post-cataract surgery anti-inflammatory, particularly given its favorable emulsion formulation (better dose uniformity vs. suspensions), high potency, and twice-daily dosing potential during the taper phase.

The shortage forces practices to reconsider their standard protocols. Key considerations:

• Formulary diversification: Practices relying exclusively on Difluprednate should consider adding Prednisolone Acetate 1% or Dexamethasone 0.1% as protocol alternatives
• Pre-surgical planning: Confirm Difluprednate availability with the patient's pharmacy before the day of surgery to avoid post-operative delays
• Patient education: Proactively inform patients about potential difficulty filling the prescription and provide backup options at the time of prescribing

Uveitis Management

For anterior uveitis — Difluprednate's second FDA-approved indication — the shortage is particularly impactful. These patients often require aggressive topical steroid therapy, and Difluprednate's superior penetration makes it a preferred choice for many uveitis specialists.

When Difluprednate is unavailable, consider:

• Prednisolone Acetate 1% at higher frequency (every 1-2 hours during acute flare)
• Dexamethasone 0.1% as a potent alternative with good availability
• Periocular or intravitreal steroid injections for severe or refractory cases

Current Availability Picture

The practical impact: patients without robust insurance coverage are often unable to afford brand-name Durezol, leading to treatment delays or non-adherence. Generic availability varies significantly by region and pharmacy.

Cost and Access Considerations

For your patients facing cost barriers:

• Discount cards: GoodRx and SingleCare can reduce generic Difluprednate to $43–$49 per 5 mL bottle when available
• Novartis copay card: For commercially insured patients using brand Durezol, the Novartis Patient Savings Co-Pay Card may reduce copays — visit copay.novartispharma.com
• Patient assistance: The Novartis Patient Assistance Foundation (NPAF) provides Durezol at no cost to qualifying uninsured patients — visit pap.novartis.com
• Prescription Hope: Offers Durezol for $70/month through their assistance program

For provider-specific pricing and availability tools, visit Medfinder for Providers.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers real-time pharmacy availability data. Your staff can use it to identify which pharmacies near your patients currently have Difluprednate in stock — saving time on phone calls and reducing patient frustration. Consider integrating a quick availability check into your pre-surgical workflow.

ASHP Drug Shortage Resource Center

Monitor the ASHP Drug Shortages page for the latest updates on Difluprednate supply. ASHP provides manufacturer-specific information and alternative therapy recommendations.

Practice Workflow Integration

Suggestions for incorporating shortage management into your practice:

1. Add a pharmacy availability check to your pre-surgical consent process
2. Prepare alternative Rx templates — have Prednisolone Acetate and Dexamethasone prescriptions ready as backups
3. Designate a staff member to track local pharmacy availability for shortage medications
4. Educate your patient coordinators about directing patients to Medfinder and discount card programs

Looking Ahead

There is no confirmed timeline for the resolution of the Difluprednate shortage. While additional generic manufacturers may eventually enter the market, the complex emulsion formulation creates a longer pathway to approval and production scale-up than typical ophthalmic generics.

Practices should plan for the shortage to continue through at least mid-to-late 2026 and maintain flexible prescribing protocols accordingly.

For related content to share with your patients, consider directing them to:

• Difluprednate shortage update for patients
• Alternatives to Difluprednate
• How to save money on Difluprednate

Final Thoughts

The Difluprednate shortage is a supply-side problem that requires demand-side flexibility. By diversifying your prescribing protocols, leveraging availability tools like Medfinder, and proactively communicating with patients about alternatives and cost-saving programs, you can minimize disruption to patient care.

For a practical guide on helping patients locate Difluprednate, see How to Help Your Patients Find Difluprednate in Stock: A Provider's Guide.